Interacciones entre fármacos antihipertensivos y alimentos;Interactions between antihypertensive drugs and food

Nutricion Hospitalaria

Volumn 27, Issue 6, 2012, Pages 1866-1875

  Jauregui Garrido B ^a   Jauregui Lobera I ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

Antihypertensive drugs; Diet; Food drugs interactions; Grapefruit juice

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

DIET; FOOD DRUG INTERACTION; GRAPEFRUIT; HUMAN; META ANALYSIS;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CITRUS PARADISI; DIET; DIURETICS; FOOD-DRUG INTERACTIONS; HUMANS;

EID: 84874743997     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2012.27.6.6127     Document Type: Review

References (125)

1. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. Journal of Hypertension 2003; 21: 1011-53.
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JNC 7-Complete Version. Hypertension 2003; 42: 1206-52.
3. De Luis Román D, Aller R, Bustamante Bustamante J. Aspectos terapéuticos de la dieta en la hipertensión arterial. NefroPlus 2008; 1: 39-46.
4. INTERSALT Cooperative Research Group. An international cooperative study of electrolyte excretion and blood pressure: results fron 24 hours urinary sodium and potassium excretion. Br Med J 1988; 297: 319-28.
5. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336 (16): 1117-24.
6. Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, Karanja N; DASH-Sodium Trial Collaborative Research Group. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001; 135 (12): 1019-28.
7. Ministerio de Sanidad y Consumo, Sociedad-Liga Española para la Lucha contra la Hipertensión Arterial. Control de la Hipertensión Arterial en España, 1996. Madrid: IDEPSA, 1996.
8. Sever P et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306 (6883): 983-7.
9. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-349.
10. Kuehl P, Zhang J, Lin J, Lin Y, Lamba J, Assem M et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis for polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
11. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 2000; 101: 1749-1753.
12. Guía europea para la investigación de interacciones medicamentosas. CPMP/EWP/560/95; 1997.
13. McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF. Effect of food on the absorption of frusemide and bumetanide in man. Br J Clin Pharmacol 1996; 42: 743-46.
14. Bard RL, Bleske BE, Nicklas JM. Food: an unrecognized source of loop diuretic resistance. Pharmacotherapy 2004; 24 (5): 630-7.
15. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21 (1): 1-17.
16. Overdiek HW, Merkus FW. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986; 40 (5): 531-6.
17. Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E. Enhancement by food of canrenone bioavailability from spironolactone. Clin Pharmacol Ther 1977; 22 (1): 100-3.
18. Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978; 3 (5): 337-51.
19. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol 2000; 14 (2): 139-46.
20. Tamargo J, coordinator. Farmacología cardiovascular. Madrid: Acción Médica; 2009.
21. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48 (5): 678-87.
22. Kirsten R, Nelson K, Molz KH, Gielsdorf W, Haerlin R. Influence of food intake on the bioavailability of urapidil in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1989; 27 (6): 298-301.
23. Pérez H, Ruiz S, Núñez H, White A, Gotteland M, Hernández A. Paraventricular-coerulear interactions: role in hypertension induced by prenatal undernutrition in the rat. Eur J Neurosci 2006; 24 (4): 1209-19.
24. Toothaker RD, Randinitis EJ, Nelson C, Kinkel AW, Goulet JR. The influence of food on the oral absorption of bevantolol. J Clin Pharmacol 1987; 27: 297-9.
25. Plosker GL, Clissold SP. Controlled Release Metoprolol Formulations: A Review of Their Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Ischaemic Heart Disease. Drugs 1992; 43: 382-414.
26. Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. Br J Clin Pharmacol 1984; 17 (Suppl. 1): 45S-50S.
27. Mäntylä R, Männistö P, Nykänen S, Koponen A, Lamminsivu U. Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol 1983; 24: 227-30.
28. Zaman R, Wilkins MR, Kendall MJ, Jack DB. The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite, diacetolol. Biopharm Drug Dispos 1984; 5: 91-5.
29. Semple HA, Xia F. Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Drug Metab Dispos 1995; 23: 794-8.
30. Asdaq SM, Inamdar MN. Pharmacodynamic and pharmacokinetic interactions of propranolol with garlic (Allium sativum) in rats. Evid Based Complement Alternat Med 2011; ID DOI:10.1093/ecam/neq076.
31. Rietz B, Isensee H, Strobach H, Makdessi S, Jacob R Cardioprotective actions of wild garlic (Allium ursinum) in ischemia and reperfusion. Mol Cell Biochem 1993; 119: 143-50.
32. Wang BO, Semple HA. Inhibition of metoprolol metabolism by amino acids in perfused rat livers. Insights into the food effect? Drug Metab Dispos 1997; 25: 287-95.
33. Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Söderlind E, et al. Impact of the intragastric location of extended reléase tablets on food interactions. J Control Release 2005; 108: 375-85.
34. Waldman SA, Morganroth J. Effects of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163-9.
35. Hashiguchi M, Ogata H, Maeda A, Hirashima Y, Ishii S, Mori Y et al. No effect of high-protein food on the steroselective bioavalilability and pharmacokinetics of verapamil. J Clin Pharmacol 1996; 36: 1022-8.
36. Kozloski GD, De Vito JM, Johnson JB, Holmes GB, Adams MA, Hunt TL. Bioequivalence of verapamil hydrochloride extendedrelease pellet-filled capsules when opened and sprinkled on food and when swallowed intact. Clin Pharm 1992; 11: 539-42.
37. Schaefer HG, Heinig R, Ahr G, Adelmann H, Tetzloff W, Kuhlmann J. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 1997; 51 (6): 473-80.
38. Heinig R. Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet 1998; 3 5(3): 191-208.
39. Beudeker HJ, van der Velden JW, van der Aar EM. Interaction profile and tolerability of barnidipine. Int J Clin Pract Suppl 2000; (114): 36-40.
40. Dewardener HE. The primary role of the kidney and salt intake in the aethiology of essential hypertension: part I. Clin Sci 1990; 79: 193-200.
41. Elliot P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, Marmot M. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Br Med J 1996; 312: 1249-53.
42. Mervaala EMA, Laakso J, Karppanen H. Cardiovascular effects of felodipine are not antagonized by dietary salt. Eur J Pharmacol 1994; 255: 73-9.
43. Chrysant SG, Weder AB, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, et al. Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. Am J Hypertens 2000; 13 (11): 1180-8.
44. Bennett WM. Drug interactions and consequences of sodium restriction. Am J Clin Nutr 1997; 65 (2 Suppl.): 678S-681S.
45. White CM. Pharmacologic, pharmacokinetic and therapeutic differences among ACE Inhibitors. Pharmacotherapy 1998; 18: 588-99.
46. Sociedad Española de Cardiología. Documento de consenso de expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular. Rev Esp Cardiol 2004; 57: 1213-32.
47. Chase SL, Sutton JD. Lisinopril: a new angiotensin-converting enzyme inhibitor. Pharmacotherapy 1989; 9 (3): 120-8; discussion 128-30.
48. Gómez HJ, Cirillo VJ, Moncloa F. The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol 1987; 9 (Suppl. 3): S27-34.
49. Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet 1988; 14 (4): 241-59.
50. Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol 1984; 22 (11): 626-9.
51. Gómez HJ, Cirillo VJ, Irvin JD. Enalapril: a review of human pharmacology. Drugs 1985; 30 (Suppl. 1): 13-24.
52. Bell J. Benazepril: a new ACE inhibitor. Anna J 1993; 20 (2): 187-8.
53. Gengo FM, Brady E. The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol 1991; 14 (8 Suppl. 4): IV44-50; discussion IV51-5.
54. Cetnarowski-Cropp AB. Quinapril: a new second-generation ACE inhibitor. DICP 1991; 25 (5): 499-504.
55. Cawello W, Boekens H, Waitzinger J, Miller U. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. Int J Clin Pharmacol Ther 2002; 40 (1): 9-17.
56. Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25 (1): 20-58.
57. Reitberg DP, Love SJ, Quercia GT, Zinny MA. Effect of food on nifedipine pharmacokinetics. Clin Pharmacol Ther 1987; 42 (1): 72-5.
58. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73-86.
59. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag 2011; 7: 605-22.
60. Tamargo J, Caballero R, Gómez R, Núñez L, Vaquero M, Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales? Rev Esp Cardiol 2006; 6 (Supl. C): 10-24.
61. Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10 (12 Pt 2): 311S-317S.
62. Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens Suppl 1997; 15 (7): S15-20.
63. Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database of Systematic Reviews 2011; 11: Art. No.: CD004934.
64. Semple HA, Koo W, Tam YK, Ngo LY, Coutts RT. Interactions between hydralazine and oral nutrients in humans. Ther Drug Monit 1991; 13 (4): 304-8.
65. Jackson SH, Shepherd AM, Ludden TM, Jamieson MJ, Woodworth J, Rogers D et al. Effect of food on oral availability of apresoline and controlled release hydralazine in hypertensive patients. J Cardiovasc Pharmacol 1990; 16 (4): 624-8.
66. Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther 1984; 36 (1): 14-8.
67. Kindler J, Rüegg PC, Neuray M, Pacha W. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine. Eur J Clin Pharmacol 1987; 32 (4): 367-72.
68. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juicedrug interactions. Br J Clin Pharmacol 1998; 46: 101-10.
69. Uno T, Yasui-Furukori N. Effect of grapefruit in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006; 1: 157-61.
70. Panchagnula R, Bansal T, Varma MV, Kaul CL. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. Pharmazie 2005; 60 (12): 922-7.
71. Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT? Eur J Pharm Sci 2005; 25: 263-71.
72. Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2010; 70: 645-55.
73. Owira PM, Ojewole JA. The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives. Cardiovasc J Afr 2010; 21: 280-5.
74. Kakar SM, Paine MF, Stewart PW, Watkins PB. 6'7'-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004; 75: 569-79.
75. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4: 281-97.
76. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337 (8736): 268-9.
77. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51 (2): 189-93.
78. Hirashima H, Uchida N, Fukuzawa I, Ishigaki S, Uchida E, Yasuhara H. Effect of a single glass of grapefruit juice on the apparent oral bioavailability of the dihydropyridine calcium channel antagonist, azelnidipine, in healthy Japanese volunteers. Jpn J Clin Pharmacol Ther 2006; 37 (3): 127-33.
79. Ohnishi A, Ohtani H, Sawada Y. Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists. Br J Clin Pharmacol 2006; 62 (2): 196-99.
80. Yajima Y, Iijima H, Yokoyama R. Influence of grapefruit juice on the plasma concentration of efonidipine hydrochloride (Landel). Yakuri To Chiryo 2003; 31 (7): 579-88.
81. Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF et al. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 2004; 76 (6): 607-17.
82. Uno T, Ohkubo T, Motomura S, Sugawara K. Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol 2006; 61 (5): 533-37.
83. Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S, Ishizaki T. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol 2000; 56 (9-10): 643-49.
84. Ohtani M, Kawabata S, Kariya S, Uchino K, Itou K, Kotaki H et al. Effect of grapefruit pulp on the pharmacokinetics of the dihydropyridine calcium antagonists nifedipine and nisoldipine. Yakugaku Zasshi 2002; 122 (5): 323-29.
85. Fuhr U, Maier-Bruggemann A, Blume H, Muck W, Unger S, Kuhlmann J et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36 (3): 126-32.
86. Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000; 67 (3): 201-14.
87. Soons P, Vogels BA, Roosemalen MC, Schoemaker HC, Uchida E, Edgar B et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50 (4): 394-403.
88. Hashimoto K, Shirafuji T, Sekino H, Matsuoka O, Sekino H, Onnagawa O, et al. Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects. Eur J Clin Pharmacol 1998; 54 (9-10): 753-60.
89. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 2006; 83 (5): 1097-105.
90. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68: 28-34.
91. Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000; 49: 49-58.
92. Bailey DG, Arnold JM, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995; 40: 135-40.
93. Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 2006; 19: 768-73.
94. Uesawa Y, Takeuchi T, Mohri K. Publication bias on clinical studies of pharmacokinetic interactions between felodipine and grapefruit juice. Pharmazie 2010; 65: 375-8.
95. Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 2010; 88 (3): 339-42.
96. Nakagawa K, Goto T. Effects of ingestion of grapefruit juice or grapefruit on the hypotensive effect and plasma concentrations of dihydropyridine calcium antagonists (amlodipine and nifedipine): a case study. Clin Exp Hypertens 2010; 32 (2): 71-5.
97. Christensen H, Asberg A, Holmboe AB, Berg KJ. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 2002; 58 (8): 515-20.
98. Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 2002; 58 (1): 45-53.
99. Ho PC, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol 2000; 56: 693-8.
100. Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol 1998; 54: 337-40.
101. Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 2001; 23 (4): 369-73.
102. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 2010; 332: 181-9.
103. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit Pglycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007; 96 (10): 2808-17.
104. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther 2005; 77 (4): 291-301.
105. Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001; 12: 361-7.
106. Lilja JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br J Clin Pharmacol 2005; 60: 659-63.
107. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 2003; 73 (3): 192-8.
108. Uesawa Y, Mohri K. Hesperidin in orange juice reduces the absorption of celiprolol in rats. Biopharm Drug Dispos 2008; 29: 185-8.
109. Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 2005; 61: 337-40.
110. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergicblocking agent celiprolol. Clin Pharmacol Ther 2004; 75: 184-90.
111. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69: 14-23.
112. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003; 73: 529-37.
113. Piao YJ, Choi JS. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res 2008; 31: 518-22.
114. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002; 72 (3): 247-55.
115. Mervaala EM, Malmberg L, Teräväinen TL, Laakso J, Vapaatalo H, Karppanen H. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. Br J Pharmacol 1998; 123: 195-204.
116. Shinozuka K, Umegaki K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expres-sion hepatic cytochrome P-450 and attenuates the hypotensive effects of nicardipine in rats. Life Sci 2002; 70: 2783-92.
117. Onrat E, Kaya D, Barutçu I. Atrioventricular complete heart block developed due to verapamil use together with honey consumption. Anadolu Kardiyol Derg 2003; 3: 353-4.
118. González JP, Valdivieso A, Calvo R, Rodríguez-Sasiaín JM, Jimenez R et al. Influence of vitamin C on the absorption and first pass metabolism of propranolol. Eur J Clin Pharmacol 1995; 48: 295-7.
119. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12: 357-62.
120. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokinet 1994; 26: 91-8.
121. Edgar B, Regårdh CG, Johnsson G, Johansson L, Lundborg P, Löfberg I et al. Felodipine kinetics in healthy men. Clin Pharmacol Ther 1985; 38: 205-11.
122. Blychert E, Edgar B, Elmfeldt D, Hedner T. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991; 31: 15-24.
123. de Andrés S, Lucena A, de Juana P. Interactions between foodstuffs and statins. Nutr Hosp 2004; 19: 195-201.
124. Jáuregui-Garrido B, Jáuregui Lobera I. Interactions between antiarrhythmic drugs and food. Nutr Hosp 2012; 27: 1399-1407.
125. Observatorio del consumo y la distribución alimentaria. Monográfico zumos y pomelo. Madrid: Ministerio de agricultura, alimentación y medio ambiente; 2010.